H5N1 Influenza
4
0
1
3
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
6 treatments under study, led by Ad4h5vtn Vaccinationtonsillar Route
Research Leaders
11 sponsors active, led by National Institute of Allergy and Infectious Diseases (NIAID)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
25%
1 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (4)
Immunogenicity and Safety of 2 Doses of Avian Influenza A (H5N1) Vaccine Administered 3 vs. 8 Weeks Apart
Experimental AD4-H5-VTN Vaccine in Healthy Volunteers
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
H5N1 Vaccine Study in Japanese Adults
Research Network
Common Treatments
- Ad4h5vtn Vaccinationtonsillar Route1
- H5n1 Vaccine Arepanrix1
- H5n1 Prepandemic Influenza Vaccine Whole Virion Vero Cell Derived Inactivated1
- H5n1 Vaccine1
- Saline As A Placebo1
Active Sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)2
- Canadian Immunization Research Network1
- IWK Health Centre1
- McGill University Health Centre/Research Institute of the McGill University Health Centre1
- Baxter Innovations GmbH1
Top Investigators
National Institute of Allergy and Infectious Diseases (NIAID)
Johns Hopkins Bloomberg School of Public Health
CIRN, Canadian Center for Vaccinology, Dalhousie University
Baxter Innovations GmbH
Related Conditions
- H5n1 Virus1
- Avian Influenza1
- Avian Influenza A Virus1